AMWL · American Well Corporation

American Well’s Q1 2026 results reflect continued operational stabilization and strategic focus on platform consolidation, as emphasized by CEO Dr. Ido Schoenberg’s commentary on technology-enabled care infrastructure gaining traction with payers and providers. Revenue declined 17.9% year-over-year to $54.9 million, driven by lower legacy revenue streams, yet exceeded internal guidance — suggesting improved forecasting and execution discipline. Gross margin held steady at 51%, supported by the $24.9 million subscription revenue (45% of total) and $28.9 million Amwell Medical Group (AMG) visit revenue (53% of total), indicating successful monetization of both SaaS and clinical service models. The $14.9 million improvement in net loss quarter-over-quarter — from ($25.2) million in Q4 2025 to ($10.3) million — was fueled by reduced R&D and sales & marketing spend, alongside a $7.0 million net gain on divestiture that partially offset ongoing operating losses. Adjusted EBITDA’s improvement to ($3.1) million — up $7.2 million sequentially — underscores meaningful progress toward the company’s stated objective of positive operating cash flow in Q4 2026. Management’s decision to narrow full-year Adjusted EBITDA guidance to ($16)–($12) million (from prior wider range) reflects growing confidence in cost control and revenue predictability, particularly as pipeline growth and customer renewals accelerate. While cash used in operations remained modest at ($0.98) million — a dramatic improvement from ($25.1) million in Q1 2025 — the balance sheet remains strong with $179.2 million in cash and equivalents and no debt, providing ample runway to execute the transformation plan without near-term financing risk. The forward-looking emphasis on AI-powered innovation and regulatory tailwinds further positions Amwell for scalable growth beyond 2026, contingent on sustained execution against its platform transition roadmap.